Current clinical status of 18F-FLT PET or PET/CT in digestive and abdominal organ oncology
| Autor: | Takashi Yoshiura, Masatoyo Nakajo, Yoriko Kajiya, Megumi Jinguji, Tohru Nihara, Masayuki Nakajo, Yoshiaki Nakabeppu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty PET-CT Radiological and Ultrasound Technology medicine.diagnostic_test business.industry Urology Gastroenterology Computed tomography Hepatology Response to treatment 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure In vivo Positron emission tomography 030220 oncology & carcinogenesis Internal medicine medicine Radiology Nuclear Medicine and imaging Radiology Bone marrow business |
| Zdroj: | Abdominal Radiology. 42:951-961 |
| ISSN: | 2366-0058 2366-004X |
| Popis: | Positron emission tomography (PET) or PET/computed tomography (CT) using 18F-3'-fluoro-3'-deoxythymidine (18F-FLT) offers noninvasive assessment of cell proliferation in human cancers in vivo. The present review discusses the current status on clinical applications of 18F-FLT-PET (or PET/CT) in digestive and abdominal oncology by comparing with 18F-fluorodeoxyglucose (18F-FDG)-PET (or PET/CT). The results of this review show that although 18F-FLT uptake is lower in most cases of digestive and abdominal malignancies compared with 18F-FDG uptake, 18F-FLT-PET can be used to detect primary tumors. 18F-FLT-PET has shown greater specificity for N staging than 18F-FDG-PET which can show false-positive uptake in areas of inflammation. However, because of the high background uptake in the liver and bone marrow, it has a limited role of assessing liver and bone metastases. Instead, 18F-FLT-PET will be a powerful tool for monitoring response to treatment and provide prognostic information in digestive and abdominal oncology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink